The investment bank upgraded the pharma stock to overweight from equal weight.
Get this delivered to your inbox, and more info about our products and services.
The bank initiated the clinical-stage biotechnology firm at a buy rating.
This darling of the Covid era has given back considerable gains in recent years, but it could be on the verge of a turnaround.
The investment bank upgraded the pharmaceutical name to buy from neutral.
The bank's research arm raised its rating on the stock to overweight from equal weight.
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
BofA analysts are bullish on this German medtech name ahead of its full-year earnings report.
